Australian and New Zealand untapped biotechnology opportunities

Focuses on biotechnology opportunities in Australia and New Zealand. Increase in investments into the Australian and New Zealand biotechnology sector; Rank of Australia among biomedical research and development cost-effective countries; Application of New Zealand's biotechnology research in fields such as forestry and human healthcare.

Strategic Australian biotechnology opportunities

Discusses the biotechnology opportunities in Australia as of April 2005. Specific core activities of Australian biotechnology companies; Number of biotechnology companies listed on the Australian Stock Exchange on September 30, 2004; Mutual recognition arrangements that exist with Australia and key international regulatory authorities.

Snapshop of current Australian biotechnology boom indicators

Presents an update on the indicators of biotechnology growth in Australia as of December 2005. Estimated public sector spending on biotechnology research & development in the period 2002-2003; Employment status in 2004; Mergers and acquisitions in the 3rd quarter of 2005.

Market capitalization of Australian stock exchange (ASX) listed biotechnology companies

Comments on the market capitalization of Australian Stock Exchange listed biotechnology companies. Background on the Australian biotechnology stock market; Factors which determine the levels of risks; Points to consider when valuing Australian biotechnology companies.

Snapshot of Singapore biotechnology boom indicators

The article discusses various reports published within the issue, including one on the biotechnology industry players in Singapore and another on a market audit survey on the Singapore biotechnology sector.

Survey commentaries and analysis on Singapore biotechnology international alliances and Singapore biotechnology boom in 2010

The article presents survey commentaries and analysis on biotechnology international alliances and biotechnology boom in Singapore in 2010. The survey revealed that the government and other key government industries are not keen in investing money in areas such as agricultural biotechnology, vaccine production, natural medicine, alternative therapeutics and plant biotechnology which have economic future globally. Most stakeholders expect international alliances and biopartnering with Singapore. They identified that the industry's strengths are biomedical and pharmaceuticals.

Survey commentaries and analysis on SWOT analysis of Singapore biotechnology boom indicators

The article presents survey commentaries and analysis on Strengths, Weaknesses, Opportunities and Threats (SWOT) analysis of biotechnology boom indicators in Singapore as of April 2006. SWOT is the process whereby the strengths and weaknesses in the internal environment are analyzed in association with the opportunities and threats arising from the external environment. The success of Singapore's biotechnology sector depends on the effectiveness and efficiency of the interface between the external and internal environments. The strengths, weaknesses, opportunities, and threats in the industry are discussed.

Survey commentaries and analysis on Singapore biotechnology venture capital, intellectual and property regulatory law

The article presents survey commentaries and analysis on biotechnology venture capital, intellectual and property regulatory law in Singapore as of April 2006. The survey revealed that the financial sector and venture capitalists lack the ability to evaluate and understand biotechnology. Some major concerns for stakeholders are the lack of experience in the litigation of cases by Singaporean law firms and the lack of strategic management of portfolios for biomedical and pharmaceutical companies and the government. Stakeholders cited the need for Singaporean laws to be amended to accommodate developments in medical devices, herbal medicine, some biological areas and pre-clinical and clinical trials.

Key advances in Thailand biotechnology

This article denotes the advances on biotechnology in Thailand.

The biotechnology and marketing interface : functional integration using mechanistic and holographic responses to environmental turbulence

This paper serves to specify and ground research into interfunctional integration in a wider theoretical context with particular reference to the interaction between technology and marketing in the biotechnology sphere. The general and specific problem areas are specified as those of interfunctional relations and the dyadic relationship between marketing and biotechnical managerial functions in particular. The contextual/organisational generative mechanisms that are likely to keep interfunctional relations at the centre of scholarly attention for some time are explored from the perspective of cybernetic theory. The law of requisite variety states that in an effective open system environmental variety is matched by internal structural variety. As organisations are faced with ever more turbulent, and complex environments, this must be matched by an increased internal complexity within the organisation. The two modes of response, namely holographic and mechanistic, both highlight the need to further our understanding of interfunctional differences. Having established the problem and its genesis, a specific research agenda is outlined as the exploration of the interfunctional differences from a decision-making perspective.

Snapshot of Malaysian biotechnology

This article deals about the top priority on Biotechnology in Malaysia.